Johns Hopkins Bloomberg School of Public Health researchers published a five-year electronic-health-record analysis of 175,000 U.S. patients with type 1 diabetes finding that those on GLP-1 receptor agonists saw a 15 percent reduction in major adverse cardiovascular events and a 19 percent reduction in end-stage kidney disease. [1] The paper appeared in Nature Medicine, dated March 2026 and propagating through specialty press into late April. [2]

Five-year MACE risk fell from 5.0 percent in the non-GLP-1 group to 4.3 percent in the GLP-1 group; ESKD risk fell from 1.9 to 1.6 percent. [1] Heart-attack risk fell roughly 21 percent, all-cause mortality roughly 16 percent, heart-failure risk roughly 18 percent. Hypoglycemia hospitalizations and diabetic-ketoacidosis hospitalizations were lower in the GLP-1 group, contradicting the long-running safety concern that drove the FDA's reluctance to extend the label past type 2 diabetes. [3]

The label question is what changes Friday. Semaglutide's only FDA kidney-cardiovascular indication is the type 2 chronic-kidney-disease label HCPLive marked at its one-year anniversary in late April. [3] The Hopkins data reads as the off-label clinical practice catching up to a class effect that pre-existed any U.S. regulatory acknowledgement; the drugs work in type 1, the prescriptions have been written, and the outcomes data now follow.

The cardiologist register has run ahead of the diabetologist register on this question for two years. The Hopkins paper hands payers and the FDA the same numerator and denominator. Whether label extension follows is now a 2026 calendar item, not a research one. The American Diabetes Association's 2026 Standards of Care already cite GLP-1s as adjunct therapy for type 1 patients with cardiovascular risk; the label is the policy infrastructure that catches up. [4]

-- NORA WHITFIELD, Chicago